Patent · US Active

Anti-CD94 antibodies and methods of use thereof

US11795228B2 · kind B2 · utility

0Cited by
0References
75Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 29, 2021
Grant dateOct 24, 2023
Priority date—
Expiry dateNov 19, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.